1,542 reports of this reaction
1.5% of all APIXABAN reports
#18 most reported adverse reaction
PULMONARY EMBOLISM is the #18 most commonly reported adverse reaction for APIXABAN, manufactured by Amneal Pharmaceuticals of New York LLC. There are 1,542 FDA adverse event reports linking APIXABAN to PULMONARY EMBOLISM. This represents approximately 1.5% of all 106,298 adverse event reports for this drug.
Patients taking APIXABAN who experience pulmonary embolism should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PULMONARY EMBOLISM is a less commonly reported adverse event for APIXABAN, but still significant enough to appear in the safety profile.
In addition to pulmonary embolism, the following adverse reactions have been reported for APIXABAN:
The following drugs have also been linked to pulmonary embolism in FDA adverse event reports:
PULMONARY EMBOLISM has been reported as an adverse event in 1,542 FDA reports for APIXABAN. This does not prove causation, but indicates an association observed in post-market surveillance data.
PULMONARY EMBOLISM accounts for approximately 1.5% of all adverse event reports for APIXABAN, making it a notable side effect.
If you experience pulmonary embolism while taking APIXABAN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.